Pharmacokinetics of novel drugs for the treatment of diabetic nephropathy新型药物治疗糖尿病肾病的药代动力学Expert Opinion on Drug Metabolism & ToxicologyIF3.42026-09-100PRE
Cardiovascular and Metabolic Outcomes of Hormone Replacement Therapy in Women Aged 65 Years and Older: A Systematic Review of Randomized Clinical Trials激素替代疗法对65岁及以上女性心血管和代谢结局的影响:随机临床试验的系统综述Clinical Pharmacology-Advances and ApplicationsIF2.52026-09-090OA
Cost-effective interventions to prevent prescription drug misuse: a systematic reviewFRONTIERS IN PUBLIC HEALTHIF3.42025-03-040OAAI
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415JCO CLINICAL CANCER INFORMATICSIF2.82022-06-011OA
Perceived social capital and binge drinking in older adults: The Health and Retirement Study, US data from 2006-2014DRUG AND ALCOHOL DEPENDENCEIF3.62020-09-0115OAAI
Advancing the Use of Patient Preference Information as Scientific Evidence in Medical Product Evaluation: A Summary Report of the Patient Preference WorkshopPATIENT-PATIENT CENTERED OUTCOMES RESEARCHIF3.12019-11-2214PREAI
HEALTHCARE UTILIZATION AND FUNCTIONAL LIMIATION AMONG OLDER ADULTS IN THE USVALUE IN HEALTHIF62019-05-010OAAI
CHANGE IN THE PREVALENCE OF DEPRESSION AMONG PEOPLE WITH HYPERTENSION BETWEEN THE JNC 7 AND ACC/AHA 2017 GUIDELINES: US NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES), 2008-2016 COHORTVALUE IN HEALTHIF62019-05-010OAAI
CONSUMER HEALTH INFORMATION TECHNOLOGY IN THE PREVENTION OF SUBSTANCE ABUSE: A SCOPING REVIEWVALUE IN HEALTHIF62019-05-010OAAI
HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH MENTAL HEALTH IN PATIENTS WITH OPIOID USE DISORDERSVALUE IN HEALTHIF62019-05-011OAAI
SELF-MONITORING BLOOD GLUCOSE AND ECONOMIC OUTCOMES IN PEOPLE WITH DIABETESVALUE IN HEALTHIF62019-05-010OAAI
Consumer Health Information Technology in the Prevention of Substance Abuse: Scoping Review预防药物滥用的消费者健康信息技术: 范围审查JOURNAL OF MEDICAL INTERNET RESEARCHIF62019-01-309OAAI
TOTAL HEALTHCARE EXPENDITURES ASSOCIATED WITH BIOLOGICAL ANTI -RHEUMATIC DRUGS USE AMONG MEDICARE BENEFICIARIES WITH RHEUMATOID ARTHRITISVALUE IN HEALTHIF62018-05-010OAAI
EMERGENCY DEPARTMENT (ED) UTILIZATION FOR DENTAL OR ORAL HEALTH RELATED CONDITIONS (DOHRC) BEFORE AND AFTER IMPLEMENTATION OF AFFORDABLE CARE ACT (ACA)VALUE IN HEALTHIF62018-05-010OAAI
Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around ValueOPEN FORUM INFECTIOUS DISEASESIF3.82018-02-0760OAAI
Future Considerations for the Evaluation of Hepatitis C Virus Treatments in Pan-Genotypic Therapy for Noncirrhotic Treatment-Naive PatientsJOURNAL OF MANAGED CARE & SPECIALTY PHARMACYIF2.92018-01-010OAAI
Aggregate Trends of Hepatitis C Virus Identification and Treatment in Maryland Corrections Fiscal Years 2012-2016JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINEIF4.12017-12-060OAAI
Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured YouthsJAMA PEDIATRICSIF182017-12-0142OAAI
Tree-based Claims Algorithm for Measuring Pretreatment Quality of Care in Medicare Disabled Hepatitis C PatientsMEDICAL CAREIF2.82017-12-0112PREAI